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that the correctional facilities, which at present have 
inadequate infection control practices and isolation 
facilities to prevent transmission of M.  tuberculosis, fully 
comply with the current guidelines to reduce the risk 
of tuberculosis spread [14,15]. 
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Gingivocrevicular transudate for HIV screening 
Clin Microbiol Infect 1997; 3: 588-590 
The use of saliva as an alternative biological fluid to 
serum in diagnosis or screening of infectious diseases by 
antibody detection has been the main subject of several 
articles in the last few years [l-61. Sahva samples can be 
obtained simply, without specialized personnel, and the 
process is non-traumatic for the patient and economic 
and poses no contamination risks for health workers. 
For these reasons, saliva samples may be of great utility 
in underdeveloped nations, where there is a severe 
shortage of personnel and specialized equipment. Saliva 
is a mixture of the secretions produced by the salivary 
glands and gingival crevicular transudate (GCT). The 
use of GCT, which has a greater concentration of 
immunoglobulins (Ig) of the IgG type than does 
complete saliva [7], seems to improve detection of such 
Ig in the samples [8]. 
An oral device without preservatives (Salivette, 
Starstedt, Leicester, UK) was used to obtain the GCT 
samples. The device is a cylinder of cotton wool con- 
tained in a polystyrene double tube with a snap top 
(price USA $0.20). The cotton wool was placed in the 
lateral gingival fold until the individual could perceive 
that it had become soft because of its absorption of 
GCT. The samples thus obtained were centrifuged at 
4000 g for 15 min, producing a supernatant which was 
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aliquoted and frozen at -80°C until processing. A 
serum sample was simultaneously obtained by vene- 
puncture from each of the individuals included in the 
study. These samples were then aliquoted and stored at  
-80°C until processed. 
A total of 183 paired samples of GCT and serum 
were analyzed (50 C D C  stage 11, 10 C D C  stage 111, 33 
C D C  stage Iv 26 risk factor individuals and 64 blood 
donors). In both types of sample, the presence of IgG 
against HIV-I and HIV-2 was detected. With GCT 
samples, we used a new dot blot (Multispot HIV- 
1 /HIV-2, Sanofi Diagnostics Pasteur, France) capable 
of discriminating between both IgG HIV-1 and IgG 
HIV-2. For the screening of serum samples, an indirect 
enzyme immunoassay (EIA) (VIDAS HIV 1+2, 
bioMkrieux, France) was used. All reactive samples 
were confirmed by Western blot (WB) (Bioblot HIV- 
I plus, Genelabs Diagnostics, Switzerland). The WB 
used combines specific proteins for HIV-1 and a 
synthetic peptide (gp36) for HIV-2 in the same strip; 
WHO criteria [9] were used for confirmation of 
screening reactivity. 
The results presented in Table 1 show that all GCT 
samples non-reactive by dot blot belonged to non- 
infected individuals (EIA negative), except for one 
sample from a patient of the C D C  stage IV group, 
which was negative by dot blot but positive by GCT 
W B  (reactivity against gp160, gp120 and gp41). The 
GCT samples reactive by dot blot correspond to 
infected individuals, with the exception of one sample 
from a non-infected individual also negative by GCT 
WB. The characteristics of this test in comparison with 
serum W B  results have been as follows: 99% sensitivity 
and 99% specificity (positive predictive value (PPV) and 
negative predictive value (NPV) were 0.9). 
Several reasons may be suggested in the case of the 
non-reactive sample from the individual belonging to 
C D C  stage IV The first is the immunologic deteriora- 
tion presented by individuals in the final stages of the 
infection, yielding a lower IgG serum concentration 
and even loss of concrete antibodies (ie.  p24 anti- 
bodies); second, GCT may therefore not present 
reactivity when analyzed by insufficiently sensitive 
techniques. The use of a more sensitive test (WB) leads 
in this case to the detection of IgG against envelope 
proteins in the GCT. The confirmed presence of HIV- 
1 envelope antibody in G C T  is highly suggestive of 
HIV-1 infection and also correlates with the reactivities 
obtained in the serum WB of this individual. 
The salivary device used presents two main 
advantages. The first and most important is that it can 
obtain an adequate volume (= 1 ml) for sample analysis 
by different techniques and storage. Second, in contrast 
to the case with other devices, IgG sample concen- 
tration does not vary so much, because the sample is 
not diluted. There is no experimental evidence that the 
concentration of Ig in GCT declines during storage, 
but any such changes would be minimal, because the 
samples were not diluted in any preservative buffer and 
they were frozen after recovery, thus minimizing the 
action of saliva enzymes. GCT samples (USA $0.20) are 
cheaper to obtain than serum samples (USA $0.60 for 
syringe +needle+ tube). Furthermore, the GCT pro- 
cess permits a single individual to collect samples from 
several patients at  once, instead of the individualized 
sample collection required with serum. 
Our  results confirm previous work by others 
[10,11] but using a simple device for sampling and 
testing. The use of GCT instead of saliva has been 
proposed in several articles [8,10,11] to facilitate the 
detection of HIV IgG due to the increased amount of 
this type of Ig. 
In conclusion, the use of dot blot together with 
the oral GCT device could offer an alternative for 
screening of infection produced by HIV in wide 
population groups, because of its low cost and easy 
application. Further studies should be performed in 
patients with advanced stages of the disease to deter- 
mine if the lloss in sensitivity could be due to the 
immunologic condition in this particular stage of the 
disease. 
Table 1 Detect ion of HIV-1 antibodies in the  serum and 
GCT of different population groups 
Group No. Dotccr  EIAscrunl m p "  
Stage I1 50 50 50 50 
Stage I11 10 10 10 10 
Stage IV 33 32 33 33 
Subjects at risk for 
HIV infection 26 0 0 0 
Blood donors 64 l b  0 0 References 
Prudencio Martinez, j o s k  Maria Eiros 
Raul Ortiz dc Lejararu 
Antonio Rodrkuez Torres 
Servicio de Microbiologia Clinica, 
Hospital Universitario, Valladolid, Spain 
Accepted 25 April 1997 
Total 183 93 93 93 1. Parrv IV. Perm KR. Mortimer PP. Sensitive assavs for viral 
, _ l ,  , , 
antibodies in saliva: an alternative to tect 011 cerum. Lancet "Samples with positive Western blot in serum and GCT. 
"Sample with negative Western blot in GCT. 1987; 2: 72-5. 
590  C l i n i c a l  M i c r o b i o l o g y  a n d  I n f e c t i o n ,  V o l u m e  3 N u m b e r  5, O c t o b e r  1997  
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
2. Parry JV, Perry KR, Panday S, Mortimer PP. Diagnosis of 
hepatitis A and B by testing saliva. J Med Virol 1989; 28: 
255-60. 
3. Thieme T, Yoshihara P, Piacentini S, Beller M: Clinical 
evaluation oforal fluid samples for diagnosis ofviral hepatitis. 
J Clin Microbiol 1992; 30: 1076-9. 
Lucht E, Albert J, Linde A, et al. Human ihmunodeficiency 
virus type l and cytomegalovirus in saliva. J Med Virol 1993; 
39. 1 5 G h 2  
The HBe Ag precursor is encoded by the 637-bp 
precore/core open reading frame starting at nucleotide 
1814 of the HBV minus strand genome (nomenclature 
according to Galibert et al [4]), The frequently 
described mutation is a G to A substitution at the 
3’ end of the pre-C gene (nucleotide 1896), which 
converts codon 28 for tryptophan (TGG) to a termina- 
tion codon (TAG) [S], resulting in the failure of HBe - . . . - - .. - . 
Frerichs R, Htoori M, Eskes N, Soe L. Comparison of saliva 
and serum for HIV surveillance in developing countries. 
Lancet 1992; 340: 1496-9. 
Akker R, Hoek J, Akker W, et al. Detection of HIV 
antibodies in saliva as a tool for epidemiological studies. 
Parry JV. A specimen of convenience. Diagn Virol 1991; 3: 
Martinez P, Ortiz de Lejarazu K, Eiros JM, et al. 
Comparison of two assays for detection of HIV antibodm 
in saliva. Eur J Clin Microbiol 1995; 14: 330-6. 
World Health Organization. AIDS. Proposed W H O  criteria 
for interpreting results fiom Western blot assays for HIV-1, 
HIV-2 and HTLV-I/HTLV-11. Wkly Epidemiol Rec 1990; 
G6mez C, Gutitrrez M, Martinez-Acacio P, Soriano V. 
Evaluation of a new saliva collection device for HIV anti- 
body screening purposes. Vox Sang 1994; 66: 244. 
Gallo D, George R, Fitchen J, Goldstein A, Hindahl M. 
Evaluation of a system using oral mucosal transudate for 
HIV-1 antibody screening and confirmatory testing. JAMA 
1997; 277: 254-8. 
AIDS 1992; 6: 953-7. 
13-15. 
65: 281-3. 
More on HBe Ag-negative mutants in chronic HBV 
infection 
Clin Microbiol Infect 1997; 3: 590-591 
Chronic infection with hepatitis B virus (HBV) leads 
to a wide spectrum of liver diseases, including asymp- 
tomatic carrier state, chronic active hepatitis, cirrhosis 
and hepatocellular carcinoma. Patients presenting with 
chronic active hepatitis typically have evidence of HBV 
replication marked by high levels of HBV DNA, HBV 
surface antigen (HBs Ag) and the e antigen (HBe Ag) 
in their serum [l]. In later stages of the disease, 
seroconversion from HBe Ag to anti-HBe antibody 
classically indicates a transition to a ‘non-replicative’ 
phase, in which necro-inflammatory activity ceases. In 
some cases, however, anti-HBe seroconversion is not 
followed by such a favorable outcome, and markers for 
HBV replication remain detectable [2]. Carman et a1 
[3] have studied such patients and found that they 
carried HBV mutants which cannot synthesize the 
precore precursor protein and therefore HBe Ag. 
Ag production and the cessation of its secretion into 
the bloodstream. It is often associated with a G to A 
silent mutation at nucleotide (nt) position 1899. The 
frequency of the nt 1896 mutation varies in different 
studies, ranging from 46% [6] to 80% [3]. This vari- 
ability led us to investigate the frequency of the nt 1896 
mutation and the presence of other putative mutations 
in a cohort of French patients. 
We analyzed 32 serum samples from chronically 
infected patients showing discordant serologic profiles, 
i.e. positive for HBs Ag and HBV DNA, negative for 
HBe Ag and positive for anti-HBe antibody. Serum 
samples were submitted to heat treatment (100 “C) for 
30 min and then clarified by centrifugation (12000g) 
for 30 min. This rapid technique for HBV DNA 
preparation had been validated in preliminary studies 
as compared either to classical proteinase K-sodium 
dodecylsulfate (SDS) lysis followed by phenol extraction 
or to NaOH treatment of the serum. We applied an 
amplification-created restriction site method derived 
from that described by Lindh et a1 [7] for detecting the 
nt 1896 G to A mutation. According to this procedure, 
the nt 1865-2058 region of HBV DNA was amplified 
using P1 primer with a mismatch at position 1893. 
When the nt 1896 G to A mutation was present, the 
194-bp P C R  product exhibited a BSU 361 restriction 
site which could be shown by enzyme digestion and 
agarose gel electrophoresis. Prior to hgestion, a plasmid 
containing a unique BSU 361 restriction site was 
added as a control for the completion of digestion. 
The specificity of the P C R  reaction was checked by 
hybridization with a digoxigenin-labeled probe specific 
for the HBV precore region. In parallel, the nt 
1728-2160 region of HBV DNA was amplified for 
the determination of nucleotide sequence using a T7 
polymerase sequencing kit (Pharmacia). 
After digestion with BSU 361, we observed three 
patterns of migration in an agarose gel among the 32 
samples tested. Five cases (16%) showed a digested 
product of 165 bp characteristic ofthe G to A mutation. 
Twenty cases (62%) showed an undigested PCR pro- 
duct of 194 bp. In seven (22%) cases, two fragments 
comigrated in the agarose gel, one of 194 bp, and one 
of 165 bp, corresponding to a mixed viral population 
(wild type and mutant). In these cases, the possibility 
of partial digestion with BSU 361 was ruled out by 
